Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 311
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | ||
| NCT01419028 | A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP) | ||
| NCT03723512 | Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study | ||
| NCT04451434 | Study of Danicopan in Participants of Japanese Descent | ||
| NCT02531867 | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan | ||
| NCT03551730 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4) | ||
| NCT03418389 | Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia | ||
| NCT07557420 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) | ||
| NCT04802083 | COVID-19 Soliris Expanded Access Protocol | ||
| NCT01522170 | aHUS Observational Long Term Follow-Up | ||
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | ||
| NCT01919346 | Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation | ||
| NCT04920370 | Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT02112994 | Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | ||
| NCT01716728 | Identification of Undiagnosed Lysosomal Acid Lipase Deficiency | ||
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | ||
| NCT05501717 | Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT02273596 | Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | ||
| NCT01194973 | An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome | ||
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | ||
| NCT06764160 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG | ||
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | ||
| NCT04551599 | A Study of the Effects of Food and Age on Danicopan | ||
| NCT04526197 | Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. | ||
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | ||
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT03218241 | Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy | ||
| NCT06677138 | PK Study of Gefurulimab SC in Healthy Chinese Adult Participants | ||
| NCT05274633 | Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT03075904 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) | ||
| NCT03056040 | ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | ||
| NCT01374360 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | ||
| NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | ||
| NCT06374264 | Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder | ||
| NCT00122330 | Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | ||
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | ||
| NCT06449001 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis |
